IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4274
Positioning
Market Dominance
Manufacturing
Medical Equipment
$75M
Gareth R. Sheridan
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl system.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$NTRB NutriBand Inc. | 33 | 28 | 40 | 19 | - | - | -114.2% | -102.4% | 28.1% | -469.0% | -464.9% | -21.9% | 0.0% | 12.0x | $75M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
NutriBand Inc. (NTRB) receives a "Avoid" rating with a composite score of 33.3/100. It ranks #4274 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Gareth R. Sheridan
Chief Executive Officer
Labor Force
10
28
35
53
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for NTRB
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for NTRB.
View All RatingsHigh margin volatility — erratic forensic earnings quality
ROE proxy -114.2% (sector -2.5%)
GM 28% vs sector 43%, OM -469% vs sector 1%
Capital turnover N/A, R&D intensity 104.1%
Rev growth -22%, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags NutriBand Inc. with an Avoid rating, assigning a composite score of 33.3/100 and 1 out of 5 stars. Ranked #4274 of 7,333 stocks, NTRB falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
NTRB's quality score of 28/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -114.2% (sector avg: -2.5%), gross margins of 28.1% (sector avg: 42.5%), net margins of -464.9% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 40/100, NTRB appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 7.14x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
NutriBand Inc.'s investment score of 35/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -21.9% vs. a sector average of 5.9% and a return on assets of -102.4% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
NutriBand Inc. is experiencing notably weak momentum with a score of just 19/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -21.9% year-over-year, while a beta of 0.66 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
With a stability score of 53/100, NTRB exhibits average financial resilience. Key stability metrics include a beta of 0.66 and a debt-to-equity ratio of 12.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
NutriBand Inc.'s short interest score of 34/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 12.00x), micro-cap liquidity risk. At $75M (micro-cap), NTRB carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
NutriBand Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4274 of 7,333 overall (42nd percentile). Key comparisons include ROE of -114.2% trailing the -2.5% sector median and operating margins of -469.0% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While NTRB currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (19) would have the largest impact on the composite score.
ROE 4506% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 34% BELOW SECTOR MEDIAN
Op. Margin 36454% BELOW SECTOR MEDIAN
AUDIT DATA AS OF OCT 31, 2025 (Q3 FY2025)
We rate NutriBand Inc. (NTRB) as Avoid with a composite score of 33.3/100 at a current price of $4.25. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in stability (53th percentile) and value (40th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (19th percentile) and quality (28th percentile) tempers our overall conviction. We assign a No Moat rating (21/100), Medium uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is widening, which provides additional comfort in the durability of the competitive position.
NutriBand Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 33.3/100 places it at rank #4274 in our full 7,333-stock universe. At $75M in market capitalization, NutriBand Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -22% combined with momentum at the 19th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 28% (-14.4pp vs sector) narrow to operating margins of -469% (-470.3pp vs sector) and net margins of -464.9%, yielding a gross-to-net conversion rate of -1655%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $4.25, NutriBand Inc. is trading near fair value based on current fundamentals. Our value factor score of 40/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at P/B of 7.1x, P/S of 23.6x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
A conservative balance sheet (12% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 33.3/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -22% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -464.9% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (19th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
We assign a Medium uncertainty rating to NutriBand Inc.. The stock presents a balanced risk profile: current negative profitability (net margin -464.9%) and weak quality scores (28th percentile). While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: current negative profitability (net margin -464.9%); weak quality scores (28th percentile); low beta of 0.66 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 53th percentile and quality factor at the 28th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (12% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate NutriBand Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-114.2%), negative profitability, weak asset returns (ROA -102.4%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — NutriBand Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, NutriBand Inc. receives a Avoid rating with a composite score of 33.3/100 (rank #4274 of 7,333). Our quantitative framework assigns a No Moat (21/100, trend: widening), Medium uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 35/100.
Our analysis does not support a constructive view on NutriBand Inc. at this time. The combination of limited competitive advantages, medium uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign NutriBand Inc. a meaningful economic moat, scoring 21/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, financial resilience, reached only 7.6/20.
The strongest moat sources are financial resilience (7.6/20) and reinvestment efficiency (7/20). Interest coverage N/A. Capital turnover N/A, R&D intensity 104.1%. These pillars form the core of NutriBand Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0/20) and margin superiority (1.8/20). ROE proxy -114.2% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Widening. ROIC has trended upward at ~431.4pp per year, and operating margin trajectory confirms strengthening economics. NutriBand Inc.'s competitive position is improving on a fundamental basis. We expect the moat score to drift upward if these trends persist over the next 12–18 months.
Key profit drivers include declining revenues (-22%) that pressure the earnings outlook. The margin cascade from 28% gross to -469% operating to -464.9% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 28th percentile.
The margin profile shows gross margins of 28%, operating margins of -469%, net margins of -464.9%. Return metrics include ROE of -114.2% and ROA of -102.4%. Relative to the Manufacturing sector, gross margins are 14.4 percentage points below the sector median of 43%, and ROE of -114.2% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 12%, revenue growth of -22%. The sector median D/E is 0%, putting NutriBand Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Below-average quality (28th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Nutriband (NASDAQ: NTRB) recently updated shareholders on its 2026 Annual Shareholders Meeting, announcing the appointment of two new directors, Alessandro Puddu and Viorica Carlig. The company also highlighted significant progress in the development of its AVERSA™ FENTANYL product, including strengthening partnerships, completing manufacturing scale-up, and engaging with the FDA. For 2026, Nutriband plans to advance towards an NDA filing, extend patent protection, and initiate a Human Abuse Liability clinical study.
Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan issued a letter to shareholders detailing key achievements in 2025, including a preferred stock dividend, progress on share price volatility reduction, and strengthening of its intellectual property. The company also made significant advancements for its lead product, AVERSA™ Fentanyl, receiving FDA feedback and completing manufacturing scale-up, while outlining priorities and outlook for 2026.
Nutriband (NASDAQ: NTRB) has agreed to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million, while retaining a 10% stake. The proceeds will fund the continued development of AVERSA Fentanyl, an abuse-deterrent transdermal opioid patch, which Nutriband believes could generate significant annual sales. The company's AVERSA technology is designed to prevent the abuse and misuse of drugs with abuse potential.
Nutriband (NASDAQ: NTRB) has signed a nonbinding letter of intent with Qvanta Group of Companies to explore collaboration in secure artificial intelligence, advanced computing, and cybersecurity technologies. This initiative aims to support Nutriband’s research and long-term product development, focusing on secure AI platforms for pharmaceutical data, data integrity frameworks for abuse-deterrent technologies, and quantum-ready modeling and simulation. The LOI does not establish a commercial partnership but paves the way for potential future agreements.
Nutriband (NASDAQ: NTRB) has responded to the Trump Administration's Executive Order designating illicit fentanyl as a weapon of mass destruction, clarifying that this does not apply to FDA-approved prescription fentanyl therapies. The company highlighted its AVERSA™ FENTANYL development, a partnership with Kindeva, which aims to create an abuse-deterrent transdermal fentanyl patch. This technology seeks to prevent abuse, misuse, diversion, and accidental exposure while ensuring continued access for patients in need.
Above 50MA
37.18%
Net New Highs
+51081